Hospital Universitario Marqués de Valdecilla -ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2004

  1. Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis

    Clinical Cancer Research, Vol. 10, Núm. 2, pp. 751-761

  2. NALP1 is a transcriptional target for cAMP-response-element-binding protein (CREB) in myeloid leukaemia cells

    Biochemical Journal, Vol. 384, Núm. 2, pp. 281-286

2003

  1. Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response

    Haematologica, Vol. 88, Núm. 12, pp. 1425-1426

2001

  1. Antiapoptotic protein Bcl-xL is up-regulated during megakaryocytic differentiation of CD34+ progenitors but is absent from senescent megakaryocytes

    Experimental Hematology, Vol. 29, Núm. 6, pp. 728-735

2000

  1. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-x(L)

    Journal of Experimental Medicine, Vol. 191, Núm. 6, pp. 977-984